Publikationen von Andrei Leonov
Alle Typen
Zeitschriftenartikel (40)
1.
Zeitschriftenartikel
34 (5), S. 393 - 407 (2024)
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins. Melanoma Research 2.
Zeitschriftenartikel
8, 100090 (2023)
Real-time tracking of drug binding to influenza A M2 reveals a high energy barrier. Journal of Structural Biology: X 3.
Zeitschriftenartikel
214, S. 18 - 27 (2023)
Anle138b interaction in α-synuclein aggregates by dynamic nuclear polarization NMR. Methods 4.
Zeitschriftenartikel
13, S. 5385 - 5394 (2022)
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils. Nature Communications 5.
Zeitschriftenartikel
48 (6), S. 1759 - 1772 (2021)
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates. European Journal of Nuclear Medicine and Molecular Imaging 6.
Zeitschriftenartikel
50 (2), S. 173 - 180 (2021)
Membrane-embedded TSPO: an NMR view. European Biophysics Journal 7.
Zeitschriftenartikel
10, 12827 (2020)
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. Scientific Reports 8.
Zeitschriftenartikel
15 (5), S. 411 - 415 (2020)
11 C radiolabeling of anle253b: A putative PET tracer for Parkinson's disease that binds to α-synuclein fibrils in vitro and crosses the blood-brain barrier. ChemMedChem 9.
Zeitschriftenartikel
1862 (2), 183064 (2020)
Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. Biochimica et Biophysica Acta. Biomembranes 10.
Zeitschriftenartikel
142 (6), S. 2704 - 2708 (2020)
Imidazole-imidazole hydrogen bonding in the pH-sensing histidine side chains of influenza A M2. Journal of the American Chemical Society 11.
Zeitschriftenartikel
9 (1), 19023 (2019)
The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers. Scientific Reports 12.
Zeitschriftenartikel
138 (4), S. 575 - 595 (2019)
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathologica 13.
Zeitschriftenartikel
11 (1), 67 (2019)
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. Alzheimer's Research and Therapy 14.
Zeitschriftenartikel
9, 9100 (2019)
Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression. Scientific Reports 15.
Zeitschriftenartikel
39 (19), S. 3752 - 3769 (2019)
Translocator protein ligand protects against neurodegeneration in the MPTP mouse model of Parkinsonism. Journal of Neuroscience 16.
Zeitschriftenartikel
34 (2), S. 255 - 263 (2019)
Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disorders 17.
Zeitschriftenartikel
10 (8), S. 3815 - 3829 (2019)
Cardiolipin promotes pore-forming activity of alpha-synuclein oligomers in mitochondrial membranes. ACS Chemical Neuroscience 18.
Zeitschriftenartikel
24 (66), S. 17606 - 17611 (2018)
Insights into cholesterol/membrane protein interactions using paramagnetic solid-state NMR. Chemistry - A European Journal 19.
Zeitschriftenartikel
1862 (4), S. 800 - 807 (2018)
Photophysics of diphenyl-pyrazole compounds in solutions and α-synuclein aggregates. Biochimica et Biophysica Acta (BBA) - General Subjects 20.
Zeitschriftenartikel
10 (1), S. 32 - 47 (2018)
The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine